EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)

Juan P Frias, Christophe De Block, Katelyn Brown, Hui Wang, Melissa K Thomas iD, Meltem Zeytinoglu, Juan M Maldonado iD

The Journal of Clinical Endocrinology & Metabolism · 17.06.2024 · 109 (7) · 1745-1753

DOI: 10.1210/clinem/dgae038 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 22.01.2024. Verfasst von Juan P Frias und 6 weiteren Autor:innen. Beteiligte Einrichtung: Velocity Clinical Research, Los Angeles, CA 90057, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

In previous SURPASS studies tirzepatide reduced hemoglobin glycated A1c (HbA1c) and body weight and improved markers of insulin sensitivity and β-cell function to a greater extent than comparators.

Objective

Explore changes in biomarkers of β-cell function and insulin sensitivity and in efficacy profiles in baseline biomarker quartile analyses with tirzepatide compared to semaglutide.

Design

Post hoc analysis of SURPASS-2 phase 3 trial (participants randomly assigned to receive weekly subcutaneous tirzepatide or semaglutide for 40 weeks).

Setting

Post hoc analysis of 128 sites in 8 countries.

Participants

A total of 1879 participants with type 2 diabetes.

Interventions

Once-weekly tirzepatide (5, 10, 15 mg) or semaglutide 1 mg. Main outcomes measures Change in homeostatic model assessment indices for pancreatic β-cell function (HOMA2-B) and for insulin resistance (HOMA2-IR), fasting glucagon, fasting C-peptide, and fasting insulin.

Results

At week 40, a greater increase in HOMA2-B was seen with tirzepatide (5, 10, 15 mg) doses (96.9-120.4%) than with semaglutide 1 mg (84.0%) (P < .05). There was a greater reduction in HOMA2-IR with all doses of tirzepatide (15.5%-24.0%) than with semaglutide 1 mg (5.1%) (P < .05). Tirzepatide 10 and 15 mg resulted in a significant reduction in both fasting C-peptide (5.2%-6.0%) and fasting glucagon (53.0%-55.3%) compared with an increase of C–peptide (3.3%) and a reduction of glucagon (47.7%) with semaglutide 1 mg (P < .05). HbA1c and body weight reductions were greater with all tirzepatide doses than semaglutide within each HOMA2-B and HOMA2-IR baseline quartile.

Conclusion

In this post hoc analysis, improvements in HbA1c and weight loss were consistent and significantly higher with tirzepatide, regardless of baseline β-cell function and insulin resistance, compared with semaglutide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Insulin ResistanceGlucagon-Like PeptidesHypoglycemic AgentsBiomarkersHumansMaleFemaleMiddle AgedGlycated HemoglobinInsulin-Secreting CellsBlood GlucoseAgedAdultDouble-Blind MethodInsulinIslets of LangerhansTreatment OutcomeGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatideSemaglutide

Stichwörter der Autor:innen

beta-cell functionincretininsulin sensitivitytirzepatidetype 2 diabetes

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsBiomarkersGlycated HemoglobinBlood GlucoseInsulinGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatideSemaglutide

Autor:innen und Institutionen

  • Velocity Clinical Research, Los Angeles, CA 90057, USA.
  • Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, University of Antwerp, 2650 Edegem, Belgium.
  • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
  • TechData Service, King of Prussia, PA 19406, USA.
  • Lilly Research Laboratories, Eli Lilly and Company, San Juan 00918, Puerto Rico.

ORCID-Profile: Melissa K Thomas, Juan M Maldonado

Förderung

  • Eli Lilly and Company

Zitieren

APA

Frias, J. P., De Block, C., Brown, K., Wang, H., Thomas, M. K., Zeytinoglu, M., & Maldonado, J. M. (2024). Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). The Journal of Clinical Endocrinology & Metabolism, 109(7), 1745-1753. https://doi.org/10.1210/clinem/dgae038

Vancouver

Frias JP, De Block C, Brown K, Wang H, Thomas MK, Zeytinoglu M, et al. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). The Journal of Clinical Endocrinology & Metabolism. 2024;109(7):1745-1753. doi:10.1210/clinem/dgae038

BibTeX
@article{Frias2024,
  author = {Frias, Juan P and De Block, Christophe and Brown, Katelyn and Wang, Hui and Thomas, Melissa K and Zeytinoglu, Meltem and Maldonado, Juan M},
  title = {Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  volume = {109},
  number = {7},
  pages = {1745--1753},
  doi = {10.1210/clinem/dgae038}
}
Kostenlos starten →